Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This is a study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in resectable locally advanced esophageal squamous cell carcinoma patients
Esophageal Squamous Cell Carcinoma
DRUG: Pembrolizumab|DRUG: Carboplatin or Cisplatin|DRUG: Docetaxel
tumor response, assess the tumor response (by irRECIST) of neoadjuvant pembrolizumab plus chemotherapy, up to 12 months|pathological response, assess the pathological responses (by College of American Pathologists(CAP) classification) of neoadjuvant pembrolizumab plus chemotherapy, up to 12 months
Percentage completion of treatment, Percentage completion of treatment in neoadjuvant pembrolizumab plus chemotherapy, up to 3 months|Incidence and severity of toxicity, Incidence and severity of toxicity defined to CTCAE v4.03 and Radiation Oncology Group (RTOG) criteria, up to 12 months|Percentage withdrawal rate from surgery, Percentage withdrawal rate from surgery due to neoadjuvant related complications, up to 3 months|Percentage delay of surgery, Percentage delay of surgery due to neoadjuvant related complications, up to 3 months|R0 resection rate, R0 resection rate, up to 3 months|Incidence and severity of post-operative complications to the Clavien-Dindo classification, Incidence and severity of post-operative complications to the Clavien-Dindo classification, up to 3 months|Disease free survival, Disease free survival, up to 24 months|Overall survival, Overall survival, up to 24 months
The primary objective of the study is to assess the tumor response (by irRECIST) and pathological response of neoadjuvant pembrolizumab plus chemotherapy (carboplatin, paclitaxel).

Secondary objectives are:

To assess completion of neoadjuvant pembrolizumab plus chemotherapy. To assess toxicities of neoadjuvant pembrolizumab plus chemotherapy To assess completion of neoadjuvant pembrolizumab plus chemotherapy. To assess withdrawal rate from surgery. To assess delay rate from surgery. To assess R0 resection rate. To assess post-operative complications. Progression Free Survival.